Article
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.
Pigment cell & melanoma research - 1 Jul 2013
Le Kaitlyn, Blomain Erik S, Rodeck Ulrich, Aplin Andrew E
Abstract excerpt
The RAF inhibitor vemurafenib achieves remarkable clinical responses in mutant BRAF melanoma patients. However, vemurafenib is burdened by acquired drug resistance and by the side effects associated with its paradoxical activation of the ERK1/2 pathway in wild-type BRAF cells. This paradoxical effect has driven the development of a new class of RAF inhibitors. Here, we tested one of these selective,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.